Business
ADIA Nutrition Inc. Ignites 2025 with February Breakthroughs, Riding Adia Med's Profitable January Triumph
Winter Park, Florida--(Newsfile Corp. - February 28, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a pioneer in healthcare innovation and regenerative medicine, concludes an extraordinary February with groundbreaking advancements in stem cell therapies, strategic partnerships, and a pivotal corporate milestone. These achievements, layered atop January's financial triumph at the Adia Med Winter Park Clinic, underscore ADIA Nutrition's unstoppable momentum toward revolutionizing healthcare, enhanc
About this update from Adia Nutrition, Inc.
[{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - February 28, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a pioneer in healthcare innovation and regenerative medicine, concludes an extraordinary February with groundbreaking advancements in stem cell therapies, strategic partnerships, and a pivotal corporate milestone. These achievements, layered atop January's financial triumph at the Adia Med Winter Park Clinic, underscore ADIA Nutrition's unstoppable momentum toward revolutionizing healthcare, enhancing investor visibility, and delivering cutting-edge solutions nationwide.","length":582,"tagName":"p"},{"type":"text","content":"February's transformative journey began on February 3, when Adia Med, the medical division of ADIA Nutrition, officially entered the $15.1 billion global stem cell market. Offering FDA-compliant treatments using 361 human cell, tissue, and cellular and tissue-based products (HCT/Ps), the clinic leverages high-quality umbilical cord stem cells to address conditions like inflammation, autoimmune disorders, and orthopedic issues-providing a U.S.-based alternative to international hubs like Panama and Switzerland. On February 5, the company took a significant step toward uplisting from OTC Pink to the OTCQB Venture Market by appointing a PCAOB-registered accounting firm for a third-party audit, boosting transparency and laying groundwork for a future Nasdaq Small Cap listing.","length":786,"tagName":"p"},{"type":"text","content":"The month gained further traction mid-February. On February 11, ADIA Nutrition tackled historical share issuance concerns, pledging to retire over 25 million undocumented shares-cutting outstanding shares by approximately 15 percent-and reinforcing its commitment to shareholder integrity. On February 13, Adia Med advanced its registration with Florida's Agency for Health Care Administration (AHCA), aiming to secure private insurance coverage for therapies like Autologous Hematopoietic Stem Cell Transplantation (aHSCT) and stem cell injectables, enhancing affordability. On February 18, a partnership with a premier FDA-approved laboratory ensured a steady supply of top-tier umbilical cord stem cell and exosome products, featuring 100 million viable cells and 3 trillion exosomes per dose, cementing Adia Med's leadership in regenerative medicine quality.","length":870,"tagN...